Trials / Recruiting
RecruitingNCT03042221
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.
Conditions
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Non-Small Cell Lung Cancer
- EGFR Gene Mutation
- ALK Gene Mutation
- ROSE Cluster 1
- BRAF V600E
Timeline
- Start date
- 2016-05-10
- Primary completion
- 2026-11-01
- Completion
- 2027-09-30
- First posted
- 2017-02-03
- Last updated
- 2026-02-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03042221. Inclusion in this directory is not an endorsement.